Anne Carpenter: An Open Source Proponent On What Pharma Does And Doesn’t Owe Academia
Executive Summary
Anne Carpenter, one of In Vivo’s 2021 Rising Leaders, talks about the growth of open source technology, putting data into action and why pharma deserves to be rewarded for evolving academic findings into marketable products for patients.
You may also be interested in...
Importation, Pay-For-Delay Reform Backed By Biden Order; March-In Rights For Pricing Suggested
The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.
COVID-19 Vaccine Refresh For Boosters Only? US FDA Position On Primary Series May Have Shifted
FDA advisors will vote 28 June on whether an Omicron component should be included in new COVID-19 booster vaccines. Following WHO recommendations, the FDA may no longer also be looking to update the primary vaccine series at this time.
Drugs From Sponsors ‘Located in Russia,’ Would Be Barred From US FDA Review By House Funding Bill
Language of the amendment cleared by appropriators in response to the Russian war against Ukraine in FDA’s fiscal year funding bill is vague, making impact of the funding ban on industry unclear. Democrats supported the amendment but said they wanted to continue to work on language to avoid “unintended consequences.” FDA would get a 10% bump in non-user fee funds under the bill.